Trial Profile
Rifaximin in the treatment of small intestinal bacterial overgrowth and IBS [irritable bowel syndrome]: double blind, randomized controlled trial (multicenter trial)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Rifaximin (Primary)
- Indications Bacterial infections; Irritable bowel syndrome
- Focus Therapeutic Use
- 20 Dec 2006 Status change
- 18 Oct 2006 New trial record.